| Authors: |
de Azambuja E; Medical Oncology Department, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (H.U.B), Université Libre de Bruxelles (U.L.B), Brussels, Belgium., Barrios CH; Oncology Research Department, Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Bartsch R; Department of Medicine 1, Division of Oncology, Medical University of Vienna, Vienna, Austria., Curigliano G; Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Dent R; Department of Medical Oncology, National Cancer Center Singapore, Singapore., Gennari A; Scuola di Medicina, Università Degli Studi Del Piemonte Orientale Amedeo Avogadro, Novara, Italy., Loi S; Translational Breast Cancer Genomics Lab - Research, Peter MacCallum Cancer Centre, Melbourne, Australia., Paluch-Shimon S; Department of Oncology, Hadassah Medical Center, Jerusalem, Israel., Pistilli B; Department of Medical Oncology, Gustave Roussy - Cancer Campus, Villejuif, France., Saura C; Breast Cancer Unit, Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Schmid P; Centre of Experimental Cancer Medicine, Cancer Research UK Barts Centre, Queen Mary University of London, London, UK., Spanic T; Patient Advocacy, Europa Donna Slovenia, Ljubljana, Slovenia., Toi M; Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan., Tolaney SM; Medical Oncology Department, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Harbeck N; Department of Obstetrics and Gynecology, Breast Center, LMU Klinikum der Universität München, Munich, Germany. |
